Weight loss injections results before and after: what clinical trials actually found

What do clinical trial results for weight loss injections actually look like?

The strongest evidence comes from large, randomised controlled trials conducted over 68–72 weeks. In STEP 1, adults using semaglutide 2.4 mg (Wegovy) lost an average of around 15% of their body weight, compared with about 2.4% on placebo. For tirzepatide (Mounjaro), SURMOUNT-1 found average reductions of roughly 20–21% at the 15 mg dose, and in the direct head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in 2025, tirzepatide produced meaningfully greater average weight loss than semaglutide 2.4 mg over the same period.

Translating percentages into real numbers: someone starting at 95 kg could expect to lose, on average, around 14 kg on semaglutide or around 19–20 kg on tirzepatide, over the course of a full year-and-a-half of treatment. Those are averages. Some participants lost considerably more; others less. Trial data tells you what is possible at population scale, not what will happen to any one person.

It is also worth knowing that the SURMOUNT-1 trial involved around 2,539 adults with obesity, and the wider tirzepatide clinical programme (including the SURPASS diabetes trials alongside SURMOUNT) enrolled more than 10,000 participants in total. The evidence base is large enough to be taken seriously, and specific enough to be honest about what it does and does not promise.

How quickly do results appear, and what does the "before and after" timeline look like?

Treatment does not start at the full dose. Both tirzepatide and semaglutide begin at a low starter dose (2.5 mg and 0.25 mg respectively) that exists mainly to let your body adjust, not to deliver maximum effect. Doses are increased gradually, typically every four weeks, guided by your prescriber.

In practice, most people notice their appetite changing within the first two to four weeks, even at the lower doses. Meaningful weight reduction (usually a few kilograms) tends to be visible from around weeks 4–8. The steepest phase of loss for most people falls between months three and nine, as the dose reaches therapeutic levels and the body adapts. Weight loss typically slows and plateaus after twelve to eighteen months, which is why trials run to 68–72 weeks rather than stopping at six months.

One pattern the trials consistently showed: people who lost at least 5% of their weight in the first three months tended to achieve larger total reductions. Early response is informative, and NICE's guidance on tirzepatide (TA1026) reflects this, it recommends reviewing continuation if less than 5% weight loss has been achieved after six months at the highest tolerated dose.

If you are planning to start treatment, the timing of your first order can matter practically. Orders placed before 12 pm Monday to Friday (even the one just before a bank holiday) are dispatched the same day once clinically approved, arriving by DPD the next working day. Worth factoring in around payday, or before you go away.

What shapes whether your results match the trial averages?

Several factors influence how an individual's results compare to the headline numbers. Dose reached matters considerably: both medicines have a clear dose-response relationship, meaning people who tolerate and reach the higher doses tend to achieve larger reductions. Not everyone does, gastrointestinal side effects like nausea, loose stools or indigestion lead some people to stay at a lower, better-tolerated dose, which is clinically valid and still produces real benefit.

Lifestyle changes alongside treatment make a measurable difference. Both medicines are licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as replacements for them. Protein intake, hydration and resistance exercise all matter more than many people expect when appetite is significantly reduced, muscle preservation becomes the priority, not just the number on the scales.

Individual biology also plays a role. Starting BMI, metabolic history, medications, and whether someone has type 2 diabetes all affect the trajectory. People with type 2 diabetes tend to lose slightly less weight than those without, across both medicines. For a fuller picture of the factors that influence outcomes, the guide to getting the best results from weight loss injections covers this in more detail.

If you are curious about whether one injection might suit you better than another, an overview of the licensed options lays out the practical differences between them. And if you have seen pictures circulating online and wondered how to read them critically, the context behind before-and-after photos is worth a look before you draw conclusions from individual images.

What do licensed UK weight loss injections not tell you, and when should you talk to a prescriber?

Clinical trial figures describe what happened in controlled conditions with regular check-ins, structured support and rigorous monitoring. Real-world results are meaningful but tend to be more variable. The NHS medicines page for tirzepatide sets out clearly what is known about how the medicine works, its common side effects, and what to watch for.

Side effects are worth understanding honestly. GI symptoms (nausea in particular) are the most common reason people struggle in the early weeks. They are usually most pronounced after starting or after a dose increase, and they typically settle within days to two weeks. Rarer but serious effects include pancreatitis: severe, persistent stomach pain that radiates to the back warrants urgent medical attention, not a wait-and-see approach.

Before-and-after results from injections you may have read about elsewhere (B12 injections marketed for weight loss, for instance) operate on completely different (and far weaker) evidence. The evidence on B12 injections and weight loss explains what the research actually shows there, separately from licensed GLP-1 medicines.

Semaglutide under the brand Saxenda (liraglutide) also has a UK weight management licence; for context on how its results compare to the newer injections, the Saxenda results page covers the trial data. For information on what treatment through a regulated online pharmacy looks like from start to finish, the injections overview is the right starting point.

If you are thinking about whether treatment could be right for you, speaking to our prescribers is the straightforward next step. A real clinician reviews your consultation the same day, not a form processor. They can give you a considered answer about which medicine, at what dose, makes sense given your health history.